NLTX logo

Neoleukin Therapeutics (NLTX) EBITDA

Annual EBITDA

-$56.48 M
+$1.94 M+3.31%

December 31, 2022

Summary

Performance

1-Year Change

+3.31%

3-Year Change

-148.67%

5-Year Change

-13.38%

15-Year Change

-13.38%

NLTX EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

High & Low

All-time High

-$7.53 M

3-Year Low

-$58.42 M

Earnings dates

Last Annual Earnings Report Date

Dec 31, 2022
NLTX previous annual earnings announcement was published on Dec 31, 2022

Next Annual Earnings Report Date

N/A
NLTX next annual earnings announcement has not yet been scheduled

OtherNLTXprofitabilitymetrics:

Annual Revenue

-
NLTX annual revenue value is unknown

Annual Net Income

-$57.56 M
NLTX annual net profit is -$57.56 million

Annual EBIT

-$59.10 M
NLTX annual earnings before interest & taxes is -$59.10 million

Annual EPS

-$20.80
NLTX annual earnings per share is -$20.80

Quarterly EBITDA

-$5.19 M
-$2.49 M-92.50%

September 30, 2023

Summary

Performance

3-Month Change

-92.5%

1-Year Change

+60.15%

3-Year Change

+46.15%

5-Year Change

+65.86%

NLTX Quarterly EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

High & Low

All-time High

$2.69 M
NLTX quarterly EBITDA is currently -292.86% below its historical high of $2.69 million

3-Year Low

-$15.15 M

Earnings dates

Last Quarterly Earnings Report Date

Sep 30, 2023
NLTX previous earnings announcement was published on Sep 30, 2023

Next Quarterly Earnings Report Date

N/A
NLTX next earnings announcement has not yet been scheduled

OtherNLTXprofitabilitymetrics:

Quarterly Revenue

-
NLTX quarterly revenue value is unknown

Quarterly Net Income

-$4.53 M
NLTX quarterly net profit is -$4.53 million

Quarterly EBIT

-$5.57 M
NLTX quarterly earnings before interest & taxes is -$5.57 million

Quarterly EPS

-$1.64
NLTX quarterly earnings per share is -$1.64

TTM EBITDA

-$32.59 M
+$7.83 M+19.37%

September 30, 2023

Summary

Performance

3-Month Change

+19.37%

1-Year Change

+43.24%

3-Year Change

+8.54%

5-Year Change

-43.49%

NLTX TTM EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

High & Low

All-time High

-$993.60 K

3-Year Low

-$59.26 M

Earnings dates

Last Quarterly Earnings Report Date

Sep 30, 2023
NLTX previous earnings announcement was published on Sep 30, 2023

Next Quarterly Earnings Report Date

N/A
NLTX next earnings announcement has not yet been scheduled

OtherNLTXprofitabilitymetrics:

TTM Revenue

-
NLTX TTM revenue value is unknown

TTM Net Income

-$34.26 M
NLTX TTM net profit is -$34.26 million

TTM EBIT

-$34.60 M
NLTX TTM earnings before interest & taxes is -$34.60 million

TTM EPS

-$12.48
NLTX TTM earnings per share is -$12.48

EBITDA Formula

EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization

Annual EBITDA

-$56.48 M
NLTX annual EBITDA is -$56.48 million

Annual Net Income

-$57.56 M
NLTX annual net profit is -$57.56 million

Annual Interest Expense

-
NLTX annual interest expense value is unknown

Annual Income Tax

-
NLTX annual income tax value is unknown

Annual D&A

$2.61 M
NLTX annual depreciation & amortization is $2.61 million

NLTX EBITDA Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year+3.3%+60.1%+43.2%
3 y3 years-148.7%+46.1%+8.5%
5 y5 years-13.4%+65.9%-43.5%

NLTX EBITDA Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-yearat high+3.4%+92.5%+192.1%at high+81.8%
5 y5-year+148.7%+3.4%+92.5%+192.1%+43.5%+81.8%
alltimeall time+650.0%+3.4%-292.9%+200.5%+3180.3%+81.8%

Neoleukin Therapeutics EBITDA History

DateAnnualQuarterlyTTM
Sep 2023
-
-$5.19 M(+92.5%)
-$32.59 M(-19.4%)
Jun 2023
-
-$2.69 M(-75.7%)
-$40.42 M(-23.6%)
Mar 2023
-
-$11.10 M(-18.4%)
-$52.88 M(-6.4%)
Dec 2022
-$56.48 M(-3.3%)
-$13.61 M(+4.5%)
-$56.48 M(-1.6%)
Sep 2022
-
-$13.02 M(-14.1%)
-$57.42 M(-3.1%)
Jun 2022
-
-$15.15 M(+3.1%)
-$59.26 M(+1.0%)
Mar 2022
-
-$14.70 M(+1.1%)
-$58.69 M(+0.5%)
Dec 2021
-$58.42 M(+47.0%)
-$14.54 M(-2.1%)
-$58.42 M(+4.2%)
Sep 2021
-
-$14.86 M(+1.9%)
-$56.06 M(+10.3%)
Jun 2021
-
-$14.58 M(+1.0%)
-$50.83 M(+11.0%)
Mar 2021
-
-$14.44 M(+18.5%)
-$45.80 M(+15.3%)
Dec 2020
-$39.73 M(+74.9%)
-$12.18 M(+26.4%)
-$39.73 M(+11.5%)
Sep 2020
-
-$9.63 M(+0.9%)
-$35.64 M(-5.4%)
Jun 2020
-
-$9.55 M(+14.0%)
-$37.68 M(+32.3%)
Mar 2020
-
-$8.37 M(+3.6%)
-$28.49 M(+25.4%)
Dec 2019
-$22.71 M(-27.4%)
-$8.08 M(-30.8%)
-$22.71 M(+20.3%)
Sep 2019
-
-$11.68 M(+3180.3%)
-$18.89 M(-15.7%)
Jun 2019
-
-$356.00 K(-86.3%)
-$22.41 M(+15.7%)
Mar 2019
-
-$2.60 M(-39.0%)
-$19.36 M(-38.7%)
Dec 2018
-$31.29 M
-$4.26 M(-72.0%)
-$31.58 M(-26.4%)
Sep 2018
-
-$15.20 M(-664.9%)
-$42.92 M(+7.9%)
Jun 2018
-
$2.69 M(-118.2%)
-$39.79 M(-29.5%)
DateAnnualQuarterlyTTM
Mar 2018
-
-$14.82 M(-5.0%)
-$56.47 M(+12.5%)
Dec 2017
-$49.82 M(+34.6%)
-$15.59 M(+29.2%)
-$50.18 M(+10.5%)
Sep 2017
-
-$12.07 M(-13.8%)
-$45.41 M(+9.1%)
Jun 2017
-
-$13.99 M(+64.2%)
-$41.62 M(+7.6%)
Mar 2017
-
-$8.52 M(-21.2%)
-$38.69 M(+4.6%)
Dec 2016
-$37.00 M(+69.3%)
-$10.82 M(+30.6%)
-$37.00 M(+14.6%)
Sep 2016
-
-$8.28 M(-25.1%)
-$32.30 M(+11.6%)
Jun 2016
-
-$11.06 M(+61.9%)
-$28.93 M(+27.7%)
Mar 2016
-
-$6.83 M(+11.8%)
-$22.66 M(+3.6%)
Dec 2015
-$21.86 M(-7.3%)
-$6.11 M(+24.3%)
-$21.86 M(-8.3%)
Sep 2015
-
-$4.92 M(+2.6%)
-$23.85 M(-5.4%)
Jun 2015
-
-$4.79 M(-20.6%)
-$25.21 M(-2.2%)
Mar 2015
-
-$6.04 M(-25.4%)
-$25.77 M(+9.6%)
Dec 2014
-$23.58 M(+171.3%)
-$8.10 M(+28.9%)
-$23.50 M(+24.3%)
Sep 2014
-
-$6.28 M(+17.4%)
-$18.91 M(+18.3%)
Jun 2014
-
-$5.35 M(+41.8%)
-$15.98 M(+39.9%)
Mar 2014
-
-$3.77 M(+7.8%)
-$11.43 M(+32.2%)
Dec 2013
-$8.69 M(+15.4%)
-$3.50 M(+4.3%)
-$8.65 M(+68.1%)
Sep 2013
-
-$3.36 M(+322.6%)
-$5.14 M(+187.7%)
Jun 2013
-
-$794.10 K(-20.1%)
-$1.79 M(+79.9%)
Mar 2013
-
-$993.60 K
-$993.60 K
Dec 2012
-$7.53 M
-
-

FAQ

  • What is Neoleukin Therapeutics annual EBITDA?
  • What is the all time high annual EBITDA for Neoleukin Therapeutics?
  • What is Neoleukin Therapeutics annual EBITDA year-on-year change?
  • What is Neoleukin Therapeutics quarterly EBITDA?
  • What is the all time high quarterly EBITDA for Neoleukin Therapeutics?
  • What is Neoleukin Therapeutics quarterly EBITDA year-on-year change?
  • What is Neoleukin Therapeutics TTM EBITDA?
  • What is the all time high TTM EBITDA for Neoleukin Therapeutics?
  • What is Neoleukin Therapeutics TTM EBITDA year-on-year change?

What is Neoleukin Therapeutics annual EBITDA?

The current annual EBITDA of NLTX is -$56.48 M

What is the all time high annual EBITDA for Neoleukin Therapeutics?

Neoleukin Therapeutics all-time high annual EBITDA is -$7.53 M

What is Neoleukin Therapeutics annual EBITDA year-on-year change?

Over the past year, NLTX annual EBITDA has changed by +$1.94 M (+3.31%)

What is Neoleukin Therapeutics quarterly EBITDA?

The current quarterly EBITDA of NLTX is -$5.19 M

What is the all time high quarterly EBITDA for Neoleukin Therapeutics?

Neoleukin Therapeutics all-time high quarterly EBITDA is $2.69 M

What is Neoleukin Therapeutics quarterly EBITDA year-on-year change?

Over the past year, NLTX quarterly EBITDA has changed by +$7.83 M (+60.15%)

What is Neoleukin Therapeutics TTM EBITDA?

The current TTM EBITDA of NLTX is -$32.59 M

What is the all time high TTM EBITDA for Neoleukin Therapeutics?

Neoleukin Therapeutics all-time high TTM EBITDA is -$993.60 K

What is Neoleukin Therapeutics TTM EBITDA year-on-year change?

Over the past year, NLTX TTM EBITDA has changed by +$24.83 M (+43.24%)